# OnCo record nct06253663 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06253663/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06253663", "NCT06253663" ;
  schema:name "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L"@en ;
  schema:alternateName "JKART-1"@en ;
  schema:description "A phase 2 trial of Brexucabtagene autoleucel, Cyclophosphamide, Fludarabine in mantle cell lymphoma, run by Kite, A Gilead Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06253663/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06253663> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-03-18" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/fludarabine/> ;
  onco:companies <https://onco.cc/companies/gilead/> .